Statins and neuromuscular pathology;Estatinas y patología neuromuscular

Revista de Neurologia

Volumn 47, Issue 1, 2008, Pages 46-51

  Turpín Fenoll, Laura ^a   Millan Pascual J ^a   Martin Estefania C ^b  

^a HOSPITAL VIRGEN DE LA LUZ   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Myopathy; Neuromuscular; Neuropathy; Statins

Indexed keywords

AMIODARONE; ATORVASTATIN; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DIGOXIN; FIBRIC ACID DERIVATIVE; FLUCONAZOLE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; MACROLIDE; MEVINOLIN; MIDAZOLAM; NICOTINIC ACID; PHENOBARBITAL; PHENYTOIN; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; RIFAMPICIN; SIMVASTATIN; SULFAPHENAZOLE; TACROLIMUS; TAMOXIFEN; TROGLITAZONE; UNINDEXED DRUG; WARFARIN;

DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; MORBIDITY; MYALGIA; MYOPATHY; NEUROMUSCULAR DISEASE; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PLEIOTROPY; PREVALENCE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

EID: 46749147539     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4701.2008230     Document Type: Review

References (56)

1. Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2486-93.
2. Carneado-Ruiz J, Sánchez-Payá J, Alfaro-Sáez A, Lezcano-Rodas M, Berenguer-Ruiz L, Mira-Berenguer F, et al. Antecedente del uso de estatina en el ictus: oportunidad de mejora en el paciente con alto riesgo vascular por aterotrombosis. Rev Neurol 2007; 45: 449-55.
3. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 2008; 17: 576-84.
4. Castilla-Guerra L, Fernández-Moreno MC, López-Chozas, Jiménez-Hernández MD. Estatinas y enfermedad cerebrovascular: nuevas perspectivas en la prevención del ictus. Rev Neurol 2007; 44: 95-100.
5. Fuentes B, Díez-Tejedor E, Gil-Núñez A, Gil-Peralta A, Matias-Guiu J. Guía para el tratamiento preventivo de la isquemia cerebral. In Díez-Tejedor E, ed. Guía para el diagnóstico y tratamiento del ictus. Barcelona: Prous Science; 2006. p. 133-83.
6. Castilla-Guerra L, Fernández-Moreno MC, Balbuena-García, López-Chozas JM, Jiménez-Hernández MD. Conocimiento sobre el tratamiento de la hiperglucemia, hipertensión arterial y antiagregación en la fase aguda del ictus por los médicos de atención primaria. Rev Neurol 2007; 45: 511.
7. Tapia-Pérez H, Sánchez-Aguilar M, Torres-Corzo J, Rodríguez-Leiva I, Herrera-González LB. Estatinas y mecanismos de protección cerebral. Rev Neurol 2007; 45: 359-64.
8. Baker SK, Samjoo IA. A neuromuscular approach to statin-related myotoxicity. Can J Neurol Sci 2008; 35: 8-21.
9. Davidson MH. Safety profiles for HMG-CoA reductase inhibitors. Drugs 2001; 61: 1917-26.
10. Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep 2007; 9: 389-96.
11. Chong PH, Boskovich A, Tevkovic N, Bart RE. Statin-associated peripheral neuropathy: review of the literature. Pharmacotherapy 2004; 24: 1194-203.
12. Zhang FL, Casey PJ. Protein prenylation: molecular mechanism and functional consequences. Annu Rev Biochem 1996; 65: 241-69.
13. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteosome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 2005; 25: 2560-6.
14. Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med 2001; 24: 258-72.
15. Moosman B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet 2004; 363: 892-4.
16. Van der Pas J, Hengstaman GJ, Ter Laak HJ, Born GF, Van Engelem BG. Diagnostic value of MHC class I statin on idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 2004; 75: 136-9.
17. Bays H. Statin safety: an overview and assessment of the data -2005. Am J Cardiol 2006; 97: 6-26.
18. Omar MA, Wilson JP, Cox TS. Rhabdomiolysis. Ann Pharmacother 2002; 36: 288-95.
19. Christopher-Stine L. Statin myopathy: an update. Curr Opin Rheumatol 2006; 18: 647-53.
20. Shanahan RL, Kerzee JA, Sandhoff BG, Carroll NM, Merenich JA. Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization. Pharmacotheraphy 2005; 25: 345-51.
21. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28: 26-35.
22. Kahani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, et al. Risks associated with statin therapy. A systematic overview of randomized clinical trial. Circulation 2006; 114: 2788-97.
23. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97: 52-60.
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
25. Oh J, Ban MR, Miskie A, Rebecca L, Pollex RL, Hegele RA. Genetics determination of statin intolerance. Lipids Health Dis 2007; 6: 7-12.
26. McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol 2007; 16: 132-43.
27. Nawarskas JJ. HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev 2005; 13: 76-9.
28. Giordano N, Senesi M, Mattii G, Batisi E, Villanova M, Gennari C. Polymyositis associated with simvastatin. Lancet 1997; 349: 1600-1.
29. Guis S, Figarella-Branger D, Matiel JP, Nicoli F, Le Fur Y, Kozak-Ribbens G, et al. In vivo and in vitro characterization of skeletal muscle metabolism in patients with stain induced adverse effects. Art Rheum 2006; 55: 551-7.
30. Corrao G, Zambon A, Bertu L, Botteri E, Leoni O, Contiero P. Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases. J Epidemiol Commun Health 2004; 58: 1047-51.
31. Gaist D, García Rodríguez LA, Huerta C, Hallas J, Sindrup SH. Are users lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 2001; 56: 931-3.
32. Abellán-Miralles I, Sánchez-Pérez RM, Pérez-Carmona N, Díaz-Marín C, Mallada-Frechín J. Mononeuropatía múltiple asociada a tratamiento con pravastatina. Rev Neurol 2006; 43: 659-61.
33. Scola RH, Trencin AP, Gernu uabu F, Piovesan EJ, Werneck LC. Simvastatin-induced mononeuropathy multiplex. Arq Neuropsiquiatr 2004; 62: 540-2.
34. Vaughan TB, Bell DS. Statin neuropathy masquerading as diabetic autoimmune polineuropathy. Diabetes Care 2005; 28: 2082.
35. Jeppensen U, Gaist D, Smith T, Sindrup SH. Statin and peripheral neuropathy. Eur J Clin Pharmacol 1999; 91: 667-8.
36. Umapathi T, Chaudhry V. Toxic neuropathy. Curr Opin Neurol 2005; 18: 574-80.
37. Ii M, Nishimura H, Kusano KF, Qin G, Yoon YS, Wecker A, et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 2005; 112: 93-102.
38. Formaglio M, Vial C. Statin induced neuropathy: myth or reality? Rev Neurol (Paris) 2006; 162: 1286-9.
39. Gaist D, Jeppesen U, Andersen M, García-Rodríguez LA, Hallas J, Sindrup SH. Statins nd risk of polyneuropathy: a case-control study. Neurology 2002; 58: 1333-7.
40. Chong PH, Seeger JD, Frankling C. Clinically relevant differences between the statins: implications for the therapeutic selection. Am J Med 2001; 111: 390-400.
41. Pascuzzi RM. Peripheral neuropathies in clinical practice. Med Clin North Am 2003; 87: 697-724.
42. Anderson JL, Muhlestein JB, Bair TL, Morris S, Weaver AN, Lappe DL, et al. Do statins increase the risk of idiopathic polyneuropathy? Am J Cardiol 2005; 95: 1097-9.
43. Backes JM, Howard PA. Association of HMG-CoA reductase inhibitors with neuropathy. Am Pharmacother 2003; 37: 274-8.
44. Lo YL, Lech TH, Loh LM, Tan CE. Statin therapy and small fibre neuropathy: a serial electrophysiological study. J Neurol Sci 2003; 208: 105-8.
45. Voermans NC, Lammens M, Wevers RA, Hermus AR, Van Engelen BG. Statin-disclosed acid maltase deficiency. J Intern Med 2005; 258: 196-7.
46. Noel B, Cerottini JP, Panizzon RG. Atorvastatin induced dermatomyositis. Am J Med 2001; 110: 670-1.
47. Fauchais AL, Iba Ba J, Maurage P, Kyndt X, Bataille D, Hachulla E, et al. Polymyositis induced or associated with lipid lowering drugs: five cases. Rev Med Intern 2004; 25: 294-8.
48. Rajabally YA, Varakantam V, Abbot R. Disorder resembling Guillain-Barré syndrome on initiation of statin therapy. Muscle Nerve 2004; 30: 663-6.
49. Tsivgoulis G, Spengos K, Karandreas N, Panaws M, Aladi A, Manta P. Presymptomatic neuromuscular disorder disclosed following statin treatment. Arch Intern Med 2006; 166: 1519-24.
50. Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and amyotrophic lateral-sclerosis like syndrome: an analysis of individual case safety reports from visigibase. Drug Saf 2007; 30: 515-25.
51. Ihara Y, Namba R, Kuroda S, Sato T, Shirabe T. Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebemone. J Neurol Sci 1989; 90: 263-71.
52. Otruba P, Kanovsky P, Hlustik P. Treatment with statins and involvement of peripheral nervous system: result of a prospective clinical and neurophysiological follow-up. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007; 151: 307-10.
53. Hansen KE, Hidebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients statin associated myopathy. Arch Intern Med 2005; 165: 2671-6.
54. Bannwarth B. Drug-induced musculoskeletal disorders. Drug Saf 2007; 30: 27-46.
55. Smith CC, Bernstein LI, Avis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 2003; 163: 688-92.
56. Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK. Simvastatin induced rhabdomiolisis followed by a MELAS syndrome. Am J Med 1993; 94: 109-10.